Biocon Biologics Expands Global Presence With Viatris Biosimilars Business Acquisition In Over 70 Countries

Biocon Biologics, a leading global biopharmaceutical company, has recently made a significant expansion in its footprint by acquiring the biosimilars business from Viatris Inc. This strategic move has allowed Biocon Biologics to broaden its presence in over 70 countries, further strengthening its position in the global biologics market.
According to the company, this agreement will go into effect on July 1, 2023, cnbctv reported.

"Following the deal closure in November 2022, this marks the first wave of countries where Viatris' operations have fully transitioned to Biocon Biologics. A robust integration plan has ensured a seamless transition of partners, people, systems, and processes across these countries," the company said in its press release.

Previously administered by Viatris in these markets, the current portfolio of commercialised biosimilars, which includes bPegfilgrastim, bTrastuzumab, bGlargine, bBevacizumab, bAdalimumab, bAspart and bEtanercept is now a part of Biocon Biologics' commercial organisation.

The business thinks that by leveraging its best-in-class R&D skills, manufacturing, supply chain, and commercial & regulatory knowledge, it would be able to increase access to a broad range of biosimilars and cater to the needs of its patients.

"This will enable Biocon Biologics to meaningfully expand the geographic reach of the existing biosimilars portfolio and future pipeline into growth markets where Viatris has existing sales infrastructure and local market expertise," said Susheel Umesh, Chief Commercial Officer of Emerging Markets at Biocon Biologics.